Nasdaq
$7.90▲ 0.13%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $490.1MShares out 62.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.30After-hours26.10.01 06:026-KKey event#●●●#●●●
Oculis Holding AG
Lionel Carnot has resigned from the Board of Directors of Oculis Holding AG, effective September 30, 2026. The company stated that the departure is a personal decision unrelated to any disagreements regarding operations or policies, and the Board will continue to operate with eight members.…more
$7.90+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.10Pre-market26.08.10 21:006-KKey event
Oculis Holding AG
Oculis Holding AG는 Accure Therapeutics로부터 신경 보호 약물 후보 물질인 Privosegtor(ACT-01)와 전임상 단계의 ACT-02에 대한 모든 권리를 인수하는 자산 매입 계약을 체결했습니다. 총 인수 대금은 380만 달러의 현금과 최대 205만 주의 보통주 발행으로 구성되며, Privosegtor 인수는 2027년 2월 28일, ACT-02 인수는 2027년 3월 31일까지 완료될 예정입니다. 이번 인수를 통해 기존 라이선스 계약이 종료되어 로열티 부담이 완화되고, 해당 자산에 대한 글로벌 상업적 권리를 확보하게 됩니다.…more
$7.90+0.13%vs prev closeView filingShare - 8.6After-hours26.08.07 05:45S-8Offering
Oculis Holding AG
Oculis Holding AG는 2023년 스톡옵션 및 인센티브 플랜에 따라 197,700주의 보통주를 신규 발행하기 위해 S-8 등록신고서를 제출했습니다. 이번 등록은 임직원 및 서비스 제공자를 대상으로 한 주식 보상 목적이며, 주당 11.31달러를 기준으로 총 2,235,987달러 규모의 신주 발행이 포함됩니다.…more
$7.90+0.13%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoOvernight26.10.22 15:00#●●●#●●●
Oculis Reports Phase 2 Biomarker Data for Optic Neuritis Candidate Privosegtor…more
Oculis announced that its optic neuritis candidate, Privosegtor, reduced neuro-damage biomarkers NfL and GFAP in a Phase 2 trial. While these results provide biological support for previously reported visual improvements, the candidate remains in clinical development.…more
$7.90+0.13%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 5d agoOvernight26.10.20 15:00
●●●●●●●● ●●●●● ●●●●●●
Oculis will present new Phase 2 biomarker data for its optic neuritis candidate, Privosegtor, at the upcoming ACTRIMS-ECTRIMS meeting. The presentation aims to provide further evidence of the drug's neuroprotective potential through analysis of specific neuro-inflammatory biomarkers.…more
$7.90+0.13%vs prev close - 6d agoOvernight26.10.19 15:30
●●●●●●●● ●●●●● ●●●●●●
Oculis has fully enrolled 176 patients for its genotype-guided Phase 3 trial of Licaminlimab for dry eye disease. The company expects to report topline results around the end of 2026, focusing on patients with the specific TNFR1 genetic variant.…more
$7.90+0.13%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report